Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Boston keratoprosthesis type 1: outcomes, complications and the importance of appropriate patient selection

Search Title by author or title

Session Details

Session Title: Cornea Surgical II

Session Date/Time: Tuesday 13/09/2016 | 08:00-10:30

Paper Time: 09:38

Venue: Hall C2

First Author: : C.Samarawickrama UK

Co Author(s): :    T. Ayoub   M. Wilkins                 

Abstract Details

Purpose:

To evaluate the outcomes of Boston type 1 keratoprosthesis (K-Pro) surgery in a cohort of patients at Moorfields Eye Hospital.

Setting:

Moorfields Eye Hospital, London.

Methods:

All K-Pro surgical cases performed between March 2011 and July 2015 were included. Medical records were reviewed and pre-operative, operative and post-operative parameters recorded.

Results:

41 eyes of 40 patients were included. Mean duration of follow-up was 30.4 months (range: 8-60). The main indication for K-Pro surgery was multiple failed grafts (49%). 15 cases (36.5%) had known optic nerve/retinal disease and mean BCVA initially improved from CF to 2/60 at 6 weeks, before slowly returning to CF over a year. In contrast, those without optic nerve/retinal disease improved mean BCVA from CF to 6/18 before declining to 6/36. There were 3 retroprosthetic membranes, 3 progressive glaucoma, 6 retinal detachments, 3 infective keratitis with 2 subsequent K-Pro extrusions and 2 cases of vitritis of which 1 progressed to endophthalmitis and loss of the K-Pro. In all 3 (7.3%) cases required removal of the K-Pro.

Conclusions:

The implantation of the Boston Kpro in high risk cases can lead to improved vision, with the main limiting factor on vision being posterior segment pathology. Significant complications mean that it should continue to be used in very selected cases.

Financial Disclosure:

NONE

Back to previous